A novel sustained-release agent based on disulfide-induced recombinant collagen hydrogels for the prevention and treatment of <i>Schistosoma</i> infections.

ABSTRACT: Schistosomiasis is commonly managed using the praziquantel, but it is only effective against adult worms and duration of action is short. Liver fibrosis will worsen if eggs are still present after stopping treatment. Therefore, this study aimed to develop a sustained drug release system for effectively preventing and treating schistosomiasis. A disulfide bond-induced three-dimensional (3D) recombinant collagen hydrogel was developed for sustained praziquantel release. Three collagen sequences were developed based on the sequence for Scl2 of S. pyogene, with different substitutions of residues for cysteine (S-VCL-S1, S-VCL-S2, and S-VCL-S3). Their properties were tested. Mice were infected with Schistosoma japonicum cercariae and treated either with praziquantel collage

SUBMITTER: Wang J 

PROVIDER: S-EPMC11792459 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature